The Oral Wegovy Sales Miss: A 'Surprise' Shortfall

The oral Wegovy pill generated about $500 million (DKK 3.2 billion) in Q2 sales, which came in slightly below consensus expectations . Weekly US prescriptions exceeded 265,000 , but pricing pressures weighed on the reported revenue number. Analysts at MarketWatch and BioSpace called it a "surprise miss" that soured what was otherwise a solid quarter .

The Quality of the Beat — Why Investors Were Skeptical

Analysts quickly noted that the earnings beat was flattered by rebate adjustments and other temporary factors, not by strong underlying demand trends . The concern: the "quality of the beat" matters more than the headline number, and temporary factors won't sustain the stock .

Revised Full-Year Guidance: Still Contracting

Novo raised its 2026 outlook for the second time, now expecting adjusted sales growth of -6% to 0% at constant exchange rates (CER), an improvement from the previous -4% to -12% range . Operating profit guidance was bumped to -3% to +4% at CER . Still, the range still projects potential contraction — a sharp contrast to Eli Lilly's projected ~25% revenue growth for 2026 .

Pipeline Writedowns: DKK 6.3 Billion in Impairments

Novo recorded non-cash impairment charges of DKK 6.3 billion in Q2 2026 against intangible pipeline assets . Of that, DKK 4.0 billion was tied to monlunabant, a CB1 receptor blocker that was terminated earlier . Separately, the ZEUS phase 3 trial of the experimental heart drug ziltivekimab failed to reduce major adverse cardiovascular events, posting a hazard ratio of 0.99 (CI 0.88–1.11) — essentially no benefit versus placebo . While the ZEUS failure occurred in July 2026, the Q2 impairment charges covered multiple failed pipeline assets, including monlunabant .

Competitive Pressure: Eli Lilly's Widening Lead

The obesity drug market is expected to exceed $100 billion in the US alone by decade's end . Within that market, Lilly's injectable Zepbound continues to expand market share rapidly, while its oral GLP-1 pill, Foundayo (orforglipron), won FDA approval in April 2026 — about three months after Novo's Wegovy pill . Foundayo is the only GLP-1 pill with no food or water restrictions, a significant convenience advantage . Lilly projects ~25% revenue growth for 2026, while Novo guides toward contraction — a stark divergence that underscores Lilly's widening lead .

CagriSema Shareholder Lawsuit

On July 28, 2026, a US federal judge ruled that Novo must face part of a securities fraud class action over allegations it misled shareholders about CagriSema's dosing and tolerability in its late-stage REDEFINE-1 trial . Judge Robert Kirsch in New Jersey found investors plausibly alleged intent to deceive . The ruling is a procedural loss for Novo — the case proceeds to discovery, though Novo has said it believes the allegations are meritless .

Positive Indicators

• Over 5 million US prescriptions of oral Wegovy since its January 2026 launch .
• Upcoming European rollout: The UK's MHRA approved the oral Wegovy pill in June 2026, giving Novo a first-to-market lead in Europe versus Lilly's orforglipron, which is not yet approved there .

The Strategic Challenge

Analysts broadly see Novo facing a patent cliff as semaglutide approaches its patent expiration gap . With CagriSema's clinical data falling short of Zepbound's efficacy and a shareholder lawsuit now advancing, Novo's next-generation pipeline looks less certain . The core concern: Novo's growth is contracting while Lilly's is accelerating, and the oral Wegovy pill — meant to be the bridge to the next cycle — faces pricing pressure and a competitive disadvantage versus orforglipron's no-restriction label . CEO Mike Doustdar has defended the economics of the Wegovy pill, arguing rising volumes and early prescription numbers show the strategy is working .

The Oral Wegovy Sales Miss: A 'Surprise' Shortfall

The oral Wegovy pill generated about $500 million (DKK 3.2 billion) in Q2 sales, which came in slightly below consensus expectations . Weekly US prescriptions exceeded 265,000 , but pricing pressures weighed on the reported revenue number. Analysts at MarketWatch and BioSpace called it a "surprise miss" that soured what was otherwise a solid quarter .

The Quality of the Beat — Why Investors Were Skeptical

Analysts quickly noted that the earnings beat was flattered by rebate adjustments and other temporary factors, not by strong underlying demand trends . The concern: the "quality of the beat" matters more than the headline number, and temporary factors won't sustain the stock .

Revised Full-Year Guidance: Still Contracting

Novo raised its 2026 outlook for the second time, now expecting adjusted sales growth of -6% to 0% at constant exchange rates (CER), an improvement from the previous -4% to -12% range . Operating profit guidance was bumped to -3% to +4% at CER . Still, the range still projects potential contraction — a sharp contrast to Eli Lilly's projected ~25% revenue growth for 2026 .

Pipeline Writedowns: DKK 6.3 Billion in Impairments

Novo recorded non-cash impairment charges of DKK 6.3 billion in Q2 2026 against intangible pipeline assets . Of that, DKK 4.0 billion was tied to monlunabant, a CB1 receptor blocker that was terminated earlier . Separately, the ZEUS phase 3 trial of the experimental heart drug ziltivekimab failed to reduce major adverse cardiovascular events, posting a hazard ratio of 0.99 (CI 0.88–1.11) — essentially no benefit versus placebo . While the ZEUS failure occurred in July 2026, the Q2 impairment charges covered multiple failed pipeline assets, including monlunabant .

Competitive Pressure: Eli Lilly's Widening Lead

The obesity drug market is expected to exceed $100 billion in the US alone by decade's end . Within that market, Lilly's injectable Zepbound continues to expand market share rapidly, while its oral GLP-1 pill, Foundayo (orforglipron), won FDA approval in April 2026 — about three months after Novo's Wegovy pill . Foundayo is the only GLP-1 pill with no food or water restrictions, a significant convenience advantage . Lilly projects ~25% revenue growth for 2026, while Novo guides toward contraction — a stark divergence that underscores Lilly's widening lead .

CagriSema Shareholder Lawsuit

On July 28, 2026, a US federal judge ruled that Novo must face part of a securities fraud class action over allegations it misled shareholders about CagriSema's dosing and tolerability in its late-stage REDEFINE-1 trial . Judge Robert Kirsch in New Jersey found investors plausibly alleged intent to deceive . The ruling is a procedural loss for Novo — the case proceeds to discovery, though Novo has said it believes the allegations are meritless .

Positive Indicators

• Over 5 million US prescriptions of oral Wegovy since its January 2026 launch .
• Upcoming European rollout: The UK's MHRA approved the oral Wegovy pill in June 2026, giving Novo a first-to-market lead in Europe versus Lilly's orforglipron, which is not yet approved there .

The Strategic Challenge

Analysts broadly see Novo facing a patent cliff as semaglutide approaches its patent expiration gap . With CagriSema's clinical data falling short of Zepbound's efficacy and a shareholder lawsuit now advancing, Novo's next-generation pipeline looks less certain . The core concern: Novo's growth is contracting while Lilly's is accelerating, and the oral Wegovy pill — meant to be the bridge to the next cycle — faces pricing pressure and a competitive disadvantage versus orforglipron's no-restriction label . CEO Mike Doustdar has defended the economics of the Wegovy pill, arguing rising volumes and early prescription numbers show the strategy is working .